White Coat Doesn’t Fit; Lifestyle and Prostate Cancer; Remotely in Clinical Trials

An oncologist — and immigrant — talks about the social and professional journey to “make the white coat fit.” (JCO Art of Oncology)

Social media celebrity Technoblade, who shared his passion for the video game Minecraft with millions of fans on YouTube and Twitter, died at the age of 23, a year after learning he had sarcoma. (CNN)

Lifestyle changes — primarily diet and physical activity — may help reduce the risk of prostate cancer in men who have a genetic predisposition for the disease. (Brigham & Women’s Hospital, European Urology)

Remote technology and other decentralization tools that limit the need for in-person visits could entice more cancer patients to participate in clinical trials. (American Cancer Society Cancer Action Network, JAMA Network Open)

Seagen announced that the chemotherapy-free combination of tucatinib (Tukysa) and trastuzumab led to “clinically meaningful” antitumor activity in a phase II trial of previously treated HER2-positive metastatic colorectal cancer.

Paclitaxel maintenance therapy after complete response to standard platinum-taxane treatment for advanced ovarian cancer did not improve overall survival and led to only a small improvement in progression-free survival. (NRG Oncology)

Adding chemotherapy to adjuvant radiation therapy significantly improved disease control and survival in anaplastic oligodendroglial tumors. (NRG Oncology)

Interim results from a phase III trial showed that adding durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved pathologic complete response in non-small cell lung cancer, AstraZeneca announced.

Tislelizumab plus chemotherapy improved overall survival in advanced/metastatic esophageal cancer by more than 6 months compared with chemotherapy alone, Novartis announced.

Negotiations have heated up in Merck’s bid to acquire cancer biotech Seagen. (Bloomberg)